Visual hallucinations caused by methylphenidate.;Alucinaciones visuales producidas por metilfenidato.

Anales de Pediatria

Volumn 72, Issue 3, 2010, Pages 229-230

  Tomas Vila M ^a   Izquierdo Quevedo, F J ^a   Cerdan Vera M T ^a   Fernandez A ^a   Artes Figueres M ^a   Revert Gomas, M ^a  

^a HOSPITAL FRANCESC DE BORJA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; COCAINE; RISPERIDONE; DOPAMINE UPTAKE INHIBITOR;

CASE REPORT; HUMAN; LETTER; VISUAL HALLUCINATION; ATTENTION DEFICIT DISORDER; CHILD; DISEASE COURSE; DISRUPTIVE BEHAVIOR; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HYPERACTIVITY; IMPULSIVENESS; PRENATAL DRUG EXPOSURE; SCHOOL CHILD; CHEMICALLY INDUCED DISORDER; HALLUCINATION; MALE;

CHILD; DOPAMINE UPTAKE INHIBITORS; HALLUCINATIONS; HUMANS; MALE; METHYLPHENIDATE;

EID: 77949270177     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2009.10.013     Document Type: Letter

References (10)

1. American Academy of Pediatrics, Committe on Quality Improvement and Subcomité on ADHD. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105 (2000) 1158-1170
2. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G et al. Methylphenidate, dexamfetamine and amoxetine for the treatament of attention deficit hyperactiviy disorder in children; produced by the Centre for Reviews and Dissemination (CRD).URL:http://www.nice.org.uk/pdf/ADHD_assesment_report.pdf.
3. Criado Alvarez J.J., and Romo Barrientos C. Variabilidad y tendencias en el consumo de metilfenidato en España. Estimación de la prevalencia del tratosno por deficit de atención con hiperactividad. Rev Neurol 37 (2003) 806-810
4. Knellwolf A., Deligne J., Chiarottu F., Auleley G.R., Palmieri S., Boisgard C.B., et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 64 (2008) 311-317
5. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of child and adolescentsh attention deficit/hyperactivity disoreder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
6. Wilens T., Pelham W., Stein M., Lerner M., Spencer T., and Wolraich M. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long term open-laben study. J Am Acad Child Adolesc Psychiatry 42 (2003) 424-433
7. Coskum M., and Zoroglu S. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol 28 (2008) 723-725
8. Rashid J., and Mitelman S. Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry 46 (2007) 945-946
9. Gross-Tsur V., Joseph A., and Shalev R.S. Hallucinations Turing methylphenidate therapy. Neurology 63 (2004) 753-754
10. Young J.G. Methylphenidate-Induced Hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr 2 (1981) 35-38